{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Verapamil&page=2",
    "query": {
      "intervention": "Verapamil",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Verapamil&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-20T00:43:23.112Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00648401",
      "title": "Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Verapamil Hydrochloride Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Verelan® PM Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-01",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648401"
    },
    {
      "nct_id": "NCT03296800",
      "title": "Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Bexagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Probenecid",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Verapamil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theracos",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2017-09-27",
      "completion_date": "2017-12-06",
      "has_results": true,
      "last_update_posted_date": "2021-07-01",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03296800"
    },
    {
      "nct_id": "NCT04233034",
      "title": "Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type1 Diabetes"
      ],
      "interventions": [
        {
          "name": "HCL",
          "type": "DEVICE"
        },
        {
          "name": "verapamil 120mg tablet",
          "type": "DRUG"
        },
        {
          "name": "non-HCL",
          "type": "DEVICE"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 113,
      "start_date": "2020-07-09",
      "completion_date": "2022-09-30",
      "has_results": true,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04233034"
    },
    {
      "nct_id": "NCT00648050",
      "title": "Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Verapamil Hydrochloride Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Verelan® PM Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2006-03",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648050"
    },
    {
      "nct_id": "NCT04467931",
      "title": "ACEI or ARB and COVID-19 Severity and Mortality in US Veterans",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypertension",
        "COVID"
      ],
      "interventions": [
        {
          "name": "ACEI/ARB",
          "type": "DRUG"
        },
        {
          "name": "Non-ACEI/ARB",
          "type": "DRUG"
        },
        {
          "name": "ACEI",
          "type": "DRUG"
        },
        {
          "name": "ARB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22213,
      "start_date": "2020-01-19",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-04-28",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04467931"
    },
    {
      "nct_id": "NCT07061574",
      "title": "A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "New Onset"
      ],
      "interventions": [
        {
          "name": "Anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "verapamil extended-release capsule",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "9 Years to 20 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-03-10",
      "completion_date": "2031-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Gainesville, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07061574"
    },
    {
      "nct_id": "NCT02912663",
      "title": "Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Verapamil and Magnesium Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Justin Fraser",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "101 Years",
        "sex": "ALL",
        "summary": "18 Years to 101 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-10-11",
      "completion_date": "2020-01-14",
      "has_results": false,
      "last_update_posted_date": "2020-06-24",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02912663"
    },
    {
      "nct_id": "NCT00733239",
      "title": "Drug Discrimination in Methadone-Maintained Humans Study 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "2-4 of the drugs listed below",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2008-08",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2012-04-18",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00733239"
    },
    {
      "nct_id": "NCT05847413",
      "title": "Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Verapamil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Benaroya Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 10,
      "start_date": "2020-05-30",
      "completion_date": "2021-12-10",
      "has_results": false,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05847413"
    },
    {
      "nct_id": "NCT04404439",
      "title": "Treatment of Tinnitus With Migraine Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tinnitus, Subjective",
        "Tinnitus"
      ],
      "interventions": [
        {
          "name": "Nortriptyline + Topiramate",
          "type": "DRUG"
        },
        {
          "name": "Verapamil + Paroxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "25 Years to 85 Years"
      },
      "enrollment_count": 78,
      "start_date": "2019-09-26",
      "completion_date": "2023-12-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-09-20T00:43:23.112Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04404439"
    }
  ]
}